Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 16;141(11):1308–1315. doi: 10.1182/blood.2022017863

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology.

PMC Copyright notice

Figure 1. — Kaplan-Meier survival of patients with NDMM according to del(1p32). The red curve corresponds to patients with del(1p32), the blue curve to patients without del(1p32). P values are determined by the log-rank test comparison. (A) Overall survival of patients with NDMM, irrespective of the treatment. (B) Progression-free survival of patients with NDMM, irrespective of the treatment. (C) Overall survival of patients treated with high-dose melphalan. (D) Progression-free survival of patients treated with high-dose melphalan.